Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 14Phase 1 4Phase NA 3Phase 1/2 3Phase 2/3 2Phase 4 1

Status

Unknown 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × aumolertinib × Clear all
NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05826483 2023-04-24

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
20 enrolled
Thoracic

Lung Neoplasms

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
174 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
42 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡